Generic Medicine Info
May be taken with or without food.
Patient w/ severe CV disorders (e.g. unstable angina, cardiac failure), loss of vision in 1 eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), hypotension (BP <90/50 mmHg), recent history of stroke or MI, known hereditary degenerative retinal disorders. Severe hepatic impairment. Concomitant use w/ nitrates of any form and nicorandil.
Special Precautions
Patient w/ anatomical deformation of the penis or haematological disorders that may predispose to priapism. Not indicated for pulmonary HTN secondary to sickle-cell disease. Mild to moderate hepatic and severe renal impairment. Childn (chronic use). Pregnancy and lactation. Patient Counselling This drug may cause dizziness and altered vision, if affected, do not drive or operate machinery. Seek medical assistance in cases of prolonged erection (>4 hr) or sudden visual or hearing loss. Monitoring Parameters Monitor BP and pulse when used concurrently w/ hypotensive drugs in the treatment of pulmonary arterial HTN.
Adverse Reactions
Headache, flushing, dyspepsia, visual disturbances (e.g. blurred vision, photophobia, chromatopsia, cyanopsia, eye irritation, eye pain and redness); dizziness, insomnia, anxiety, vertigo, epistaxis, nasal congestion, pyrexia, GI disturbances (e.g. diarrhoea, vomiting), priapism; skin rashes, erythema, alopecia, limb/back pain, myalgia, facial oedema, fluid retention, paraesthesia, UTI, dyspnoea, cough, rhinitis, sinusitis, bronchitis, cellulitis, sudden decrease or loss of hearing, anaemia, leucopenia, gynaecomastia, urinary frequency or incontinence, haematuria, seizures, cerebrovascular haemorrhage, transient ischaemic attack, palpitations, syncope, HTN, hypotension. Rarely, hypersensitivity reactions, NAION causing permanent loss of vision, retinal haemorrhage.
Potentially Fatal: Serious CV events (e.g. MI, arrhythmias, tachycardia, unstable angina).
Drug Interactions
Symptomatic HTN may occur when used w/ alpha-blockers. Reduced clearance w/ CYP3A4 inhibitors (e.g. cimetidine, delavirdine, erythromycin, itraconazole, ketoconazole). Increased plasma concentrations w/ HIV-protease inhibitors particularly by ritonavir-boosted regimens. Decreased plasma concentrations w/ CYP3A4 inducers (e.g. rifampicin, bosentan).
CIMS Class
Drugs for Erectile Dysfunction / Other Cardiovascular Drugs
ATC Classification
G04BE03 - sildenafil ; Belongs to the class of drugs used in erectile dysfunction.
Disclaimer: This information is independently developed by CIMS based on sildenafil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in